WordNet

an overactive thyroid gland; pathologically excessive production of thyroid hormones or the condition resulting from excessive production of thyroid hormones (同)thyrotoxicosis
protrusion of the eyeball from the socket

PrepTutorEJDIC

『…なしに』,を持たないで,を使わないで / 《条件を表す句を作って》『もし…がなければ』 / 《動名詞を伴って》『…しないで[は]』,せずに / 《付帯状況のないこと》…しないで / 《古》《場所》『…を外に』 / 《限度》『…[の限度]を越えて』 / 外に,外部に / 外部 / もし…でなければ(unless)
甲状腺機能高進症(バセドウ病,神経過敏症などを起こす)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 甲状腺機能亢進症の診断 diagnosis of hyperthyroidism
2. バセドウ眼症（グレーブス眼症：眼窩疾患）の病因および臨床的特徴 pathogenesis and clinical features of graves ophthalmopathy orbitopathy
3. 甲状腺機能亢進症およびバセドウ病の神経学的症状 neurologic manifestations of hyperthyroidism and graves disease
4. 成人における甲状腺機能亢進症の臨床症状の概要 overview of the clinical manifestations of hyperthyroidism in adults
5. 小児および思春期における甲状腺機能亢進症の臨床症状および診断 clinical manifestations and diagnosis of hyperthyroidism in children and adolescents

English Journal

Pleural effusion in the setting of graves' disease and congestive heart failure: a case report.

Kapur S, Olarewaju A.AbstractSESSION TITLE: Pleural Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Hyperthyroidism is a rare cause of pleural effusion. We report a case of pleural effusion associated with Grave's disease in a patient with congestive heart failure.
Chest.Chest.2014 Mar 1;145(3 Suppl):257A. doi: 10.1378/chest.1771261.
SESSION TITLE: Pleural Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Hyperthyroidism is a rare cause of pleural effusion. We report a case of pleural effusion associated with Grave's disease in a patient with congestive he
PMID 24638418

A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice.

Neumann S1, Nir EA, Eliseeva E, Huang W, Marugan J, Xiao J, Dulcey AE, Gershengorn MC.Author information 1Laboratory of Endocrinology and Receptor Biology (S.N., E.N., E.E., M.C.G.), National Institute of Diabetes and Digestive and Kidney Diseases, and Division of Pre-Clinical Innovation (W.H., J.M., J.X., A.E.D.), National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892.AbstractBecause the TSH receptor (TSHR) plays an important role in the pathogenesis of thyroid disease, a TSHR antagonist could be a novel treatment. We attempted to develop a small molecule, drug-like antagonist of TSHR signaling that is selective and active in vivo. We synthesized NCGC00242364 (ANTAG3) by chemical modification of a previously reported TSHR antagonist. We tested its potency, efficacy, and selectivity in a model cell system in vitro by measuring its activity to inhibit stimulation of cAMP production stimulated by TSH, LH, or FSH. We tested the in vivo activity of ANTAG3 by measuring its effects to lower serum free T4 and thyroid gene expression in female BALB/c mice continuously treated with ANTAG3 for 3 days and given low doses of TRH continuously or stimulated by a single administration of a monoclonal thyroid-stimulating antibody M22. ANTAG3 was selective for TSHR inhibition; half-maximal inhibitory doses were 2.1 μM for TSHR and greater than 30 μM for LH and FSH receptors. In mice treated with TRH, ANTAG3 lowered serum free T4 by 44% and lowered mRNAs for sodium-iodide cotransporter and thyroperoxidase by 75% and 83%, respectively. In mice given M22, ANTAG3 lowered serum free T4 by 38% and lowered mRNAs for sodium-iodide cotransporter and thyroperoxidase by 73% and 40%, respectively. In conclusion, we developed a selective TSHR antagonist that is effective in vivo in mice. This is the first report of a small-molecule TSHR antagonist active in vivo and may lead to a drug to treat Graves' disease.
Endocrinology.Endocrinology.2014 Jan;155(1):310-4. doi: 10.1210/en.2013-1835. Epub 2013 Dec 4.
Because the TSH receptor (TSHR) plays an important role in the pathogenesis of thyroid disease, a TSHR antagonist could be a novel treatment. We attempted to develop a small molecule, drug-like antagonist of TSHR signaling that is selective and active in vivo. We synthesized NCGC00242364 (ANTAG3) by
PMID 24169564

Refined association of TSH receptor susceptibility locus to Graves' disease in the Chinese Han population.

Liu BL1, Yang SY, Liu W, Xue LQ, Chen X, Pan CM, Gu ZH, Zhan M, Zhang XM, Liang J, Gao GQ, Du WH, Yuan GY, Ying R, Zhao SX, Song HD.Author information 1State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrinology and Metabolism, Molecular Medicine Center, Ruijin Hospital Affiliated to Shanghai Jiaotong University (SJTU) School of Medicine, Shanghai 200025, China.AbstractBACKGROUND: Convincing evidence has demonstrated the association of TSH receptor (TSHR) with Graves' disease (GD) in the Chinese Han population.
European journal of endocrinology / European Federation of Endocrine Societies.Eur J Endocrinol.2014 Jan 1;170(1):109-19. doi: 10.1530/EJE-13-0517. Print 2014 Jan.
BACKGROUND: Convincing evidence has demonstrated the association of TSH receptor (TSHR) with Graves' disease (GD) in the Chinese Han population.OBJECTIVE: The aim of this study was to identify the causal variants for GD in the region encompassing TSHR by a refining association study.DESIGN AND METHO
PMID 24144966